



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/152126/>

Version: Accepted Version

---

**Article:**

Gevaert, AB, Adams, V, Bahls, M et al. (2020) Towards a personalised approach in exercise-based cardiovascular rehabilitation: How can translational research help? A 'call to action' from the Section on Secondary Prevention and Cardiac Rehabilitation of the European Association of Preventive Cardiology. *European Journal of Preventive Cardiology*, 27 (13). pp. 1369-1385. ISSN: 2047-4873

<https://doi.org/10.1177/2047487319877716>

---

© The European Society of Cardiology 2019. This is an author produced version of a paper published in the *European Journal of Preventive Cardiology*. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

# Towards a personalized approach in exercise-based cardiovascular rehabilitation: How can translational research help?

## A call to action from the Section on Secondary Prevention and Cardiac Rehabilitation of the European Association of Preventive Cardiology

Andreas B. Gevaert<sup>1,2</sup>, Volker Adams<sup>3</sup>, Martin Bahls<sup>4,5</sup>, T. Scott Bowen<sup>6</sup>, Veronique Cornelissen<sup>7</sup>,  
Marcus Dörr<sup>4,5</sup>, Dominique Hansen<sup>8,9</sup>, Harel M.C. Kemps<sup>10</sup>, Paul Leeson<sup>11</sup>, Emeline M. Van  
Craenenbroeck<sup>1,2</sup>, Nicolle Kränkel<sup>12,13#</sup>

# Corresponding author

<sup>1</sup> Research Group Cardiovascular Diseases, GENCOR Department, University of Antwerp,  
Antwerp, Belgium;

<sup>2</sup> Department of Cardiology, Antwerp University Hospital (UZA), Edegem, Belgium;

<sup>3</sup> Department of Molecular and Experimental Cardiology, TU Dresden, Heart Centre Dresden,  
Dresden, Germany;

<sup>4</sup> University of Greifswald, Department of Internal Medicine B, Greifswald, Germany;

<sup>5</sup> German Centre for Cardiovascular Research (DZHK), partner site Greifswald, Greifswald,  
Germany;

<sup>6</sup> School of Biomedical Sciences, University of Leeds, Leeds, United Kingdom;

<sup>7</sup> Department of Rehabilitation Sciences, KULeuven, Leuven, Belgium;

<sup>8</sup> Hasselt University, Faculty of Rehabilitation Sciences, REVAL, BIOMED, Diepenbeek, Belgium;

<sup>9</sup> Heart Centre Hasselt, Jessa Hospital, Hasselt, Belgium;

<sup>10</sup> Máxima Medical Centre, Centre FLOW, Eindhoven, The Netherlands;

<sup>11</sup> Oxford Cardiovascular Clinical Research Facility, Radcliffe Department of Medicine, University of  
Oxford, Oxford, United Kingdom;

<sup>12</sup> Department of Cardiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin,  
Germany;

<sup>13</sup> German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.

Running head: Personalized medicine in cardiac rehabilitation

Keywords: exercise, cardiac rehabilitation, personalized medicine, response, immune system,  
machine learning, big data, animal models

# correspondence to: Nicolle Kränkel, PD Dr. rer. nat.  
Charité – Universitätsmedizin Berlin  
Campus Benjamin Franklin, Dept. of Cardiology  
Hindenburgdamm 30, 12203 Berlin, Germany  
fax: +49-(0)30-450-513999  
phone: +49-(0)30-450-522246  
email: nicolle.kraenkel@charite.de

Acknowledgements:

TSB is supported by a Medical Research Council UK New Investigator award (MR/S025472/1). EMVC is supported by Fund for Scientific Research Flanders (Senior Clinical Investigator fellowship) and Koning Boudewijnstichting (Fund Joseph Oscar Waldmann-Berteau 2015). NK receives project-specific funding

by the German Centre for Cardiovascular Research (DZHK; 81X2100238 and 81X2100243), the German Foundation of Heart Research (F/39/17) and the German Diabetes Foundation (FP-0421-2018).

All authors certify that they have no conflicts of interest to disclose.

Word count: 195 (abstract) + 5360 (main text) + 1402 (reference 1-50) = 6957 (max 8700).

Supplemental material: reference 51-155

## **Abstract**

The benefit of regular physical activity and exercise training for the prevention of cardiovascular and metabolic diseases is undisputed. Many molecular mechanisms mediating exercise effects have been deciphered. Personalized exercise prescription can help patients in achieving their individual greatest benefit from an exercise-based cardiac rehabilitation programme. Yet, we still struggle to provide truly personalized exercise prescriptions to our patients.

In this position paper, we address novel basic and translational research concepts that can help us understand the principles underlying the inter-individual differences in the response to exercise, and identify early on who would most likely benefit from which exercise intervention. This includes hereditary, non-hereditary and sex-specific concepts. Recent insights have helped us to take on a more holistic view, integrating exercise-mediated molecular mechanisms with those influenced by metabolism and immunity. Unfortunately, while the outline is recognizable, many details are still lacking to turn the understanding of a concept into a roadmap ready to be used in clinical routine. This position paper therefore also investigates perspectives on how the advent of 'big data' and the use of animal models could help unravel inter-individual responses to exercise parameters and thus influence hypothesis building for translational research in exercise-based cardiac rehabilitation.

### **1. Introduction**

Epidemiological and interventional studies have demonstrated a benefit of regular physical activity and exercise for the prevention of cardiovascular and metabolic diseases.<sup>1-4</sup> Exercise acts in a pleiotropic manner, addressing cardiac contractile and diastolic properties, muscle anabolic and catabolic pathways, substrate metabolism, and regulatory processes governing tissue perfusion and energy storage.<sup>5,6</sup>

While physiological research of the past decades allowed us to understand these principal interactions, crucial questions remain on how to effectively implement exercise interventions in clinical therapy. Access and compliance to CR programmes remains a critical factor in the success of an exercise intervention, which requires a highly motivated multi-disciplinary team.<sup>7</sup> But basic and translational research can also help, addressing questions regarding the personalization of exercise prescription, in order to improve efficacy of exercise interventions throughout the cardio/vascular/metabolic continuum. Why do some patients not respond to exercise-based cardiac rehabilitation (CR), and how can we identify them early on? What drives the difference in response to CR in men and women? How is the response to exercise influenced by metabolism, immunity and their interaction?

In addition to that, research methodology is rapidly advancing, bringing different views on translation of biochemical findings into the clinics. How will the advent of 'big data' influence hypothesis building for translational research in CR? What is the sense and nonsense of using animal models in modern CR research?

In this position paper, we aim to address these future challenges for basic and translational research in exercise-based CR. We critically review recent studies dealing with the most important yet unanswered questions in the field, both in preclinical and clinical research. Finally, we pinpoint gaps in current evidence that deserve intensified attention in future research.


### **2. Future targets and open questions in translational cardiac rehabilitation research**

While exercise-based intervention programmes are recommended in primary and secondary cardiovascular prevention,<sup>8,9</sup> it has also become clear that exercise parameters – type, intensity, duration, frequency – differentially address cardio-vascular and metabolic endpoints, and that the quality and quantity of the response differs significantly between participants. In addition to improving implementation, it is the personalization of exercise interventions that is an important focus of current and future research.

### 2.1 Why do some patients not respond?

The improvement in

maximal aerobic capacity (peak oxygen uptake,  $VO_2\text{peak}$ ) following exercise-based CR is related to survival in a wide range of cardiovascular diseases, independent of other important risk factors.<sup>10–12</sup> Even small increments in  $VO_2\text{peak}$  result in substantially lower risk for all-cause and cause-specific mortality.<sup>3</sup> Although trials that investigated the effects of exercise-based CR on exercise capacity have consistently shown favourable and clinically significant changes,<sup>13,14</sup> a large variability is seen in the individual training response (relative change in  $VO_2\text{peak}$  following training,  $\Delta VO_2\text{peak}$ ). This variability exists both in healthy subjects and in patients with established cardiovascular disease, when exposed to similar exercise programs.<sup>12,15,16</sup> Recent studies have shown that up to 33% of patients fail to demonstrate a meaningful increase in  $VO_2\text{peak}$  in response to CR, despite adequate compliance to training. These ‘non-responders’ show a decrease in  $VO_2\text{peak}$ , or an increase within the test-retest variability of  $VO_2\text{peak}$  measurement (generally accepted to be  $\pm 6\%$ ).<sup>16–18</sup> The mechanisms driving this variability in  $\Delta VO_2\text{peak}$  are not well understood, nor do we have good predictors for the response to exercise intervention. Possible contributing factors are summarized in **Figure 1**. As we are moving into an era of personalized medicine, and exercise therapy needs to be individually tailored in order to



**Figure 1:** Known factors possibly influencing the response to exercise training. These factors are grouped as cardiac, non-cardiac, external and comorbidities. They possibly influence baseline  $VO_2\text{peak}$  and/or  $\Delta VO_2\text{peak}$ , and are themselves determined by genetic, epigenetic, and environmental factors and drugs, nutrition and sex. CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease,  $VO_2\text{peak}$  = peak oxygen uptake,  $\Delta VO_2\text{peak}$  = relative change in  $VO_2\text{peak}$  following exercise training.

generate the best response within the greatest safety margin, this is a field of research that requires urgent attention.

One way of addressing this line of research is by performing 'secondary' responder analyses on existing datasets of original publications. This can be accomplished by quantifying the number of non-responders and responders to different types of exercise interventions. For example, Williams et al. combined data from different laboratories that had compared training volumes ranging between high and moderate intensities, in populations of both healthy subjects and patients with established cardiovascular disease.<sup>19</sup> When exercise was performed with great amounts and high intensities, the likelihood of subjects increasing their exercise capacity was significantly greater. Similarly, Montero et al. showed that healthy non-responders to an exercise training intervention did increase their  $\text{VO}_2\text{peak}$  when subjected to greater training volumes.<sup>20</sup> Yet, the evidence regarding the additional beneficial effects of higher exercise intensities is still conflicting.<sup>21</sup> One could argue that the main determinant for improvements in exercise capacity is the total energy expenditure rather than the exercise intensity in these subjects. More comparative exercise intervention studies are needed to determine the inter-individual variability in exercise capacity caused by different types of exercise programs.

It still remains to be elucidated which phenotypic and genotypic characteristics predict the response of a patient to these specific exercise interventions. Previous studies already suggested that in addition to exercise training characteristics (e.g. intensity, volume, type), common personal characteristics like age, sex, body mass index, and baseline physical fitness predict between 15-21% of variability in  $\Delta\text{VO}_2\text{peak}$ .<sup>13,15,17,19</sup> Moreover, an additional physiological factor that may influence  $\Delta\text{VO}_2\text{peak}$  in patients with chronic heart failure (HF) is the circulatory response to acute exercise.<sup>22,23</sup> Considering the relatively low predictability of these factors, other more important factors that affect  $\Delta\text{VO}_2\text{peak}$  likely still need to be discovered.

Heritability explains more than 50% of the inter-individual differences in cross-sectionally measured  $\text{VO}_2\text{peak}$ .<sup>24,25</sup> In addition, the Heritage Family study demonstrated that the change in  $\text{VO}_2\text{peak}$  to exercise training intervention is also largely (47%) determined by heritable factors (i.e. genetic, epigenetic or familial environmental factors).<sup>26</sup> Heritability of training-induced changes in haemodynamic response and skeletal muscle characteristics are also relatively high.<sup>27,28</sup> Most importantly, the heritability of  $\Delta\text{VO}_2\text{peak}$  was independent of baseline  $\text{VO}_2\text{peak}$ .<sup>29</sup> This implies that even subjects with a low aerobic capacity may still substantially benefit from exercise training during CR.

Previous research has used several approaches to improve our understanding of the genetics underlying the variability in  $\text{VO}_2\text{peak}$  and  $\Delta\text{VO}_2\text{peak}$ . In the late 1990s Montgomery et al. assessed left-ventricular wall thickness as a proxy for the response to exercise intervention in 140 army recruits.<sup>30</sup> Subjects with a specific mutation in the gene for the angiotensin converting enzyme showed no improvement in left ventricular mass, while in subjects without this mutation left ventricular mass increased by 22-26%. After this publication, 'The human gene map for performance and health-related fitness phenotypes' was created.<sup>31</sup> Even though more than 200 autosomal gene variants and quantitative trait loci have been identified from this study, the authors noted that data was mainly derived from underpowered sample sizes. Therefore this study did not provide compelling evidence that DNA sequence variants in a given gene are associated with human variation in fitness and

performance traits.<sup>31</sup> Interaction between gene variants and disease modifying factors add to the complexity. For example, a single nucleotide polymorphism (SNP) in the *FTO* gene is associated with higher risk for adiposity, but this interaction term was weaker in physically active people.<sup>32</sup>

A means to overcome the focus on a single gene or locus could be transcriptome wide RNA expression profiling studies. Timmons et al. identified 11 SNPs in skeletal muscle, which were responsible for nearly 50% of the heritability of  $\Delta\text{VO}_2\text{peak}$  in healthy subjects.<sup>33</sup> Genome-wide association studies could also provide unbiased insight into the genetics underlying baseline  $\text{VO}_2\text{peak}$  as well as  $\Delta\text{VO}_2\text{peak}$ . Bouchard et al. discovered a total of 39 SNPs significantly associated with  $\Delta\text{VO}_2\text{peak}$ .<sup>34</sup> Unfortunately, there was no overlap between the genes identified by Timmons et al. and those reported by Bouchard et al.<sup>35</sup> Another large genome-wide association study compared SNPs in 1520 elite athletes with SNPs in 2760 non-athletes, and identified only a single SNP (in the *GALNTL6* gene) that was more common in athletes.<sup>36</sup> Hence, while previous studies have started to use hypothesis-free methods to improve our understanding of the genetics underlying  $\text{VO}_2\text{peak}$  and  $\Delta\text{VO}_2\text{peak}$ , there is still a long way to go.

Post-translational modifications may also influence protein function. Indeed, several non-coding RNA species have been linked to  $\text{VO}_2\text{peak}$  or  $\Delta\text{VO}_2\text{peak}$ . In healthy subjects, microRNAs are released into the circulation even after acute exercise, and exercise training induces long-term changes in their expression.<sup>37,38</sup> In a rat model of HF, Souza et al. identified a set of 14 cardiac microRNAs of which expression was influenced by exercise training.<sup>39</sup> Other studies have identified additional exercise-responsive microRNAs in animal models of different cardiovascular diseases.<sup>38</sup> To date, only two small studies have assessed the effect of exercise training on microRNA expression in human patients with established cardiovascular disease.<sup>40,41</sup> Taurino et al. showed that *miR-92a* and *miR-92b* were upregulated after exercise-based CR in patients with coronary artery disease, coinciding with a downregulation of their gene targets.<sup>40</sup> Xu et al. identified 3 miRNA dysregulated by acute exercise in HF patients, but a clear correlation with  $\text{VO}_2\text{peak}$  was not found.<sup>41</sup> More extensive studies, including larger numbers of patients and screening for more miRNA, are still needed before reliable conclusions can be drawn.

Personalization of therapy also means that target parameters need to be chosen according to the clinical need of the patient, based on their underlying morbidities and risk profile. This is not necessarily always  $\text{VO}_2\text{peak}$ , but can be improved submaximal exercise parameters, increased cardiac function, better glucose handling, reduced inflammation, or improved vascular stiffness.<sup>42-46</sup> Of note, target parameters of the exercise intervention might even change over time in each patient.

- *To summarize, the change in  $\text{VO}_2\text{peak}$  to exercise training shows large inter-individual variability. Understanding how such inter-individual differences emerge is important, as a lower response is linked to poorer outcomes.  $\Delta\text{VO}_2\text{peak}$  seems to be regulated by the interaction between heritable factors and lifestyle – including exercise parameters, SNPs, and non-coding RNAs – but individual targets have yet to be confirmed. We need controlled randomized studies using multi-omics techniques (transcriptomics, genomics, proteomics and metabolomics) to identify potential pathways in a ‘systems biology’ approach. The complex interaction between lifestyle and heritable factors likely explains a large part of the individual*

response to exercise training, and future studies should aim to improve our understanding of this interaction.

## 2.2 The potential role of sex differences in response to CR

In general,  $VO_{2peak}$  is ~15% lower in women compared to men.<sup>47</sup> Intriguingly, however, women seem to experience better clinical outcomes following exercise training, despite similar improvements in exercise capacity.<sup>48,49</sup> While sex-specific effects thus likely play a key role in the clinical benefits associated with exercise interventions, the mechanisms responsible for these benefits remain poorly understood.

Cardiac physiology as well as pathophysiology are markedly different between men and women. The main differences are summarized in **Table 1**. For a more extensive overview, we refer the reader to existing reviews.<sup>50–52</sup>

Table 1: Selected sex differences in cardiac physiology and pathophysiology

Subject	Sex difference	Ref.
Epidemiology: risk factors	Premenopausal women have lower blood pressure compared to men, which is lost after menopause	53
	When present, risk factors (hypertension, cholesterol levels, diabetes) are more often uncontrolled in women	54–57
Epidemiology: cardiac disease	Epicardial coronary artery disease is less common in women	58
	Heart failure: higher prevalence of preserved EF in women and of reduced EF in men	59
	Acute coronary syndromes: in women more often due to spontaneous coronary artery dissection, Takotsubo syndrome, and microvascular angina	60,61
Cardiovascular structure and function	LV volumes are smaller in women, even after adjustment for body size	62
	LV EF is higher in women and the increase in EF with age is larger in women	63
	Reduction in LV systolic long axis contraction with age is larger in women	64
	Increased vascular and LV stiffness in women	62
Cardiomyocyte function	Ion handling and rhythmicity differs in women, leading to higher rest heart rate, shorter PR and longer QT segments	65,66
	Altered calcium handling in female cardiomyocytes, myofibrils require more time to relax	67
	Female cardiac mitochondria suffer less oxidative damage under stress	68
	Cardiomyocytes have higher protein kinase A activity in women	69
	Cardiomyocyte loss with ageing is higher in women	70
Response to treatment	Women show higher mortality after coronary revascularization and cardiac surgery	71,72
	Response to cardiac resynchronization therapy may be better in women	73

Abbreviations: EF = ejection fraction, LV = left ventricular

Sex-specific hormones may explain part of these differences. In pre vs. postmenopausal women of similar age, blood pressure is lower, and left ventricular end-systolic volume, ejection fraction and filling rate are larger.<sup>74</sup> The vasodilating properties of oestrogen may play a role.<sup>75</sup> Also, RNA sequencing in cardiomyocytes revealed more than 600 genes with sexually dimorphic expression patterns.<sup>69</sup> This adds to genetic differences due to male specific Y-chromosomal gene expression and differences in epigenetics (histone and DNA modifications, non-coding RNA expression).<sup>52</sup> Thus, in addition to the obvious endocrine differences between men and women, a variety of anatomical, genetical and molecular differences exists within the heart. These may influence not just cardiovascular disease progression, but also affect secondary prevention strategies.

While central hemodynamic differences likely explain some of the sex-specific effects in response to CR,<sup>50</sup> other factors are also involved. It is well established that cardiac disorders induce secondary impairments to the periphery, including endothelial and skeletal muscle dysfunction, which are closely linked to symptoms of exercise intolerance and prognosis.<sup>76</sup> Surprisingly, it is still largely unclear how sex modulates the crosstalk of mechanisms governing the loss of endothelial, skeletal and cardiac function. A few studies have revealed that in patients with HF, mitochondrial enzymes in skeletal muscle show either no major changes or more pronounced deficits in men compared to women, with a greater shift towards glycolytic enzymes and type IIX fatigable fibres in men.<sup>77,78</sup> In response to an aerobic endurance training intervention, evidence has revealed minor differences in terms of skeletal muscle biochemistry, with reports suggesting men with HF can increase the content of the slow myosin heavy chain isoform towards similar levels to that observed at baseline in women.<sup>79</sup> Thus, women may experience a greater preservation of muscle oxidative function compared to men with HF, which could help to explain why women demonstrate greater clinical benefits after CR.<sup>48</sup> The mechanisms underpinning the sex-specific differences in muscle physiology and effects of exercise intervention remain unclear. Hormonal effects of oestrogen regulation on mitochondrial dynamics and/or a preferential shift towards fatty acid oxidation in women may play a role,<sup>80,81</sup> but more extensive measures of muscle function and physiology and higher sample sizes are still required to confirm this.

In addition to skeletal muscle alterations, endothelial dysfunction also develops in HF patients, both in men and women.<sup>82</sup> Yet little data is available to clearly demonstrate whether any sex-specific alterations are present following CR in patients. Recent evidence from animals models of HF have shown that high-intensity interval training can attenuate endothelial dysfunction in both female and male rats, which seems to act via mechanisms specifically lowering oxidative stress in males and increasing endothelial nitric oxide synthase expression in females.<sup>83,84</sup> Whether these molecular benefits are paralleled in male and female patients with HF remains unclear. Furthermore, sex-specific substrate utilisation could play a key role in the exercise response in women and may fill the above-mentioned gap in the literature with regards to the effectiveness of exercise-based CR. One example is that women rely on carbohydrates to a lesser extent but have a higher content of intramyocellular lipids.<sup>85</sup>

While CR programs clearly reduce the risk of all-cause and cardiac-related mortality and improve quality of life, directly extrapolating these findings from men to women remains fraught with complexities since women have consistently been under-represented in previous trials.<sup>86</sup> In large meta-analyses and randomized controlled trials, the amount of women recruited was 11-28%.<sup>50</sup> Given

that women are also ~40 % less likely to enrol in CR and have a significantly lower adherence to the interventions compared to men,<sup>87,88</sup> the need to better understand sex-specific mechanisms in response to exercise training will first require rapid improvement in CR recruitment and adherence of women. Identification of sex-specific targets is likely to substantially improve outcomes following CR programmes by optimising training regimes.

Nonetheless, women seem to benefit at least as much from exercise-based CR as men.<sup>48,89,90</sup> The most recent Cochrane reviews which assessed the benefits of exercise-based CR concluded that exercise improves cardiovascular mortality and hospitalization (in patients with coronary artery disease) and improves health-related quality of life (in patients with coronary artery disease or HF).<sup>91,92</sup> The authors also clearly state that evidence for benefits of exercise-based CR in women is currently insufficient. Given the above mentioned physiological and pathophysiological differences between men and women, we cannot assume that exercise regimes which worked for men will also be effective for women.

- *To summarize, important differences exist in the response to CR in men and women. Besides obvious differences in cardiovascular and skeletal muscle structure, function and physiology, the underlying hormonal and molecular mechanisms are still understudied. Identification of sex-specific targets might further improve outcomes after CR.*

### **2.3 Immune-metabolism interactions and inflammation**


Both enhanced activation and impaired resolution of inflammation are major underlying principles of cardiovascular and metabolic pathologies.<sup>93</sup> Regular exercise training has been shown to lower systemic and vascular inflammatory load within a few weeks of intervention.<sup>46</sup> This has been partly attributed to active secretion of anti-inflammatory myokines from skeletal muscle.<sup>94</sup> While biochemical interactions of some myokines have been deciphered, it remains a major task to chart the network of biochemical interactions between energy demand by skeletal muscle contractile activity (affected by exercise parameters, such as duration, type and frequency) and the fine-tuning of inflammatory mechanisms. The recent years have brought a refinement in our understanding of inflammation in atherosclerosis, including the appreciation of resolution of inflammation as an active process, distinct from inhibition of inflammation, as well as the tight interactions between immune cell activation and their energy metabolism. Only a fraction of these newly understood mechanisms has been exploited in the context of the cardiovascular effects of regular exercise training.

*Resolution of inflammation versus anti-inflammation:* The inability to resolve an ongoing inflammatory process is a hallmark of inflammatory degenerative processes, including atherosclerosis. On the one hand, innate immune-activating signals - ligands of pattern-recognition receptors, such as modified lipids - do not disappear in atherosclerosis, as it would happen in a 'normal' injury. On the other hand, the production of pro-resolving mediators appears to be dysregulated. Anti-inflammatory therapies have been employed more or less successfully in secondary cardiovascular prevention. However, therapeutic success appears to depend on the inflammatory signalling mechanism targeted, likely interleukin-1 $\beta$  and interleukin-6 signalling, and may be flawed by increased incidence of lethal infections.<sup>95,96</sup> In addition, blocking inflammation also appears to block resolving mechanisms, the removal of apoptotic particles and cell debris as well as the induction of regenerative processes.<sup>97</sup> The termination of an acute inflammatory response is normally governed by both the decay of pro-inflammatory signals, as well as the active production of pro-resolving factors.<sup>98</sup> A number of studies

support the ability of exercise - ranging from a single session of high-intensity interval exercise to a 3-month multicomponent exercise programme – to reduce cellular responsiveness to toll-like receptor-mediated signalling, induced by damage-associated molecular patterns.<sup>99–101</sup>

Dietary interventions targeting synthesis of specialized resolving mediators (SPM) have been tested for some time now and it becomes evident that both, the dosage and the formulation might be relevant to their success in cardiovascular prevention.<sup>102</sup> In contrast, only few studies have systematically addressed the effects of exercise intervention on the release of SPMs – resolvins, lipoxins, protectins and maresins – but the existing literature indicates an increase in SPM release by regular exercise.<sup>103–105</sup> This might be attributed to acute and chronic effects: strain and acute release of pro-inflammatory mediators are associated with SPM release in acute high-intensity exertion, while chronic effects of exercise intervention might be connected to the exercise-mediated shift in macrophage polarization towards the M2-like phenotype.<sup>103,105,106</sup> M2-like macrophages are better suited to perform efferocytosis than the M1-like phenotype and it is during efferocytosis that SPMs are released.<sup>107</sup> Thus, we know that regular exercise is associated with a shift towards the more pro-resolving macrophage spectrum, as well as higher levels of pro-resolving mediators, but we do not know which exercise parameters (e.g. intensity, volume, type) could be used to boost this effect, nor whether a combination with dietary approaches to supplement SPMs could potentiate the effects of exercise intervention on cardiovascular inflammation (**Figure 2**).

**Energy metabolism and inflammation:** From tumour biology, we know that increased glycolysis and glutaminolysis provide energy flexibility to the cell and generate intermediates that feed into anabolic processes - probably the reason why glycolysis is preferred over oxidative phosphorylation by proliferating tumour cells.<sup>108–110</sup> In a similar manner, glycolysis is preferred by activated and proliferating myeloid and lymphoid cells<sup>111</sup> and stimulating glycolysis can activate macrophages.<sup>112</sup> In addition, M1-type macrophages feature a ‘broken’ Krebs cycle, with increased output of intermediates that serve as substrates in the synthesis of pro-inflammatory mediators, or are pro-inflammatory



mediators in themselves.<sup>113 114,115</sup> In contrast, 'alternative' M2-like macrophages favour oxidative phosphorylation and fatty acid oxidation.<sup>116,117</sup> Indeed, oxidative phosphorylation was a prerequisite of M2-type phenotypic macrophage polarization.<sup>117</sup>

Of note, the complex spectrum of M2-like macrophage phenotypes recognized with their diverse roles in atherosclerosis, have not been charted in detail for their inflammation-resolving and energy metabolism phenotype yet, nor regarding the effect of exercise in their polarization. Similarly, NK cells and various T lymphocyte populations react to acute and chronic exercise and contribute to both, polarization of innate immune cells and functionality of various tissues and organs, including distinct fat depots (perivascular, subcutaneous, visceral).<sup>118</sup>

Both the amount and type of energy substrates provided and physical exercise can affect the phenotype of monocytes and macrophages.<sup>112,119–122</sup> Energy sensors, such as AMP-dependent kinase, can be targeted by both diet and exercise. On the way to personalized lifestyle-based therapies, we need to learn more about the integration of exercise parameters (e.g. type, intensity, frequency, volume) with diet (e.g. macronutrient composition, amount and timing of eating/fasting) and pharmacological means to modulate energy metabolism and (thereby) activation state of inflammatory cells.<sup>123–127</sup> Of note, activation of the relevant mechanisms might shift between individuals, being influenced by a number of factors such as hormonal status/sex, age, pharmacotherapy and co-morbidities as well as genetic background.<sup>128–130</sup>

- *To summarize, macrophage phenotype shift, leading to reduced release of pro-inflammatory mediators and an increased release of pro-resolving mediators, might well be a nexus of exercise-mediated anti-inflammatory and metabolic cardio-protective effects. The available seminal data, however, requires a better resolution: continuously improved techniques of single-cell immunophenotyping<sup>131</sup> and assessment of cellular metabolism<sup>132</sup> allow for the fine-mapping of immune-inflammatory interactions and can be used to develop diagnostic tools, assessing individual response to exercise and personalizing exercise parameters. In addition, better understanding of the cellular and molecular nodes of the immuno-metabolic network might help to optimize exercise parameters on an individual level to improve cardio-vascular and metabolic benefit, potentially in combination with pharmacological and diet-based approaches.*

### **3. Challenges and opportunities in translational CR research methodology**

The advent of high-throughput molecular techniques, single-cell diagnostics and organs-on-a-chip have opened countless opportunities in exercise research, but some important challenges have surfaced simultaneously. How can we successfully pinpoint important findings within these vast datasets? And if computers can handle increasingly complex tasks, what is the use of animal models in the future?

#### **3.1 Impact of 'big data' and artificial intelligence on translational research in CR**

As analytical techniques evolve, new challenges arise with regards to handling the enormous amount of data they generate. This is especially true in the area of genomics, epigenomics, proteomics and metabolomics, but also applies to datasets obtained from large clinical trials or registries, and epidemiological research.<sup>133</sup> These datasets cannot be readily viewed on any computer, which complicates human pattern recognition. Moreover, the analysis of 'big data' requires additional

statistical precaution, taking into account the increased 'noise' of high-throughput techniques.<sup>134</sup> Novel 'data mining' techniques have been developed to derive relationships and statistical inference from these datasets, often relying on some form of artificial intelligence. These techniques, grouped under the term 'machine learning', can be either supervised (the user determines the relation between subjects) such as traditional regression analysis, or unsupervised (the computer determines the relation between subjects), such as clustering analysis.<sup>135,136</sup>

Some of these novel techniques have already been applied to translational exercise research. In 2009, Goud et al. set up a cluster-randomized trial in 21 CR centres, comparing effects of a computerized decision support system to standard care.<sup>137</sup> In centres implementing the decision support system, concordance with CR guideline recommendations were modestly increased, reducing both over- and under-treatment. Further efforts have been made with regard to artificial intelligence-based exercise prescription.<sup>138-142</sup> Most of these studies describe a framework to automate exercise prescription based on patient demographics, comorbidities, test results and reason for referral. Randomized clinical trials evaluating these fully computerized exercise prescription are still lacking. Finally, the vast amount of data obtained from wearable devices opens up possibilities for data-driven personalization strategies. For example, one study succeeded in predicting active energy expenditure (a predictor of  $\Delta\text{VO}_2\text{peak}$ ) from photo-plethysmographic heart rate measurements, even in patients under beta blocker therapy.<sup>143</sup>

But many more possibilities of 'big data' and machine learning exist in the field of CR, which we will demonstrate at the hand of two examples from other areas within cardiovascular research: imaging and phenotyping.

Imaging is especially suited for the application of machine learning because images contain a rich amount of data both within the image itself and through extraction of quantitative features.<sup>135</sup> Furthermore, powerful computational approaches to handle image data have undergone extensive development within academic clinical research and non-medical fields such as facial recognition and image searching.<sup>144</sup> Combined with recent availability of large imaging datasets,<sup>145</sup> this has meant artificial intelligence approaches to identify images, automatically quantify image features and predict disease from the patterns in the image have developed rapidly within cardiology and radiology.<sup>135</sup> As a result, automated quantification is now entering clinical use, but broader diagnostic application will require robust clinical validation before adoption.<sup>146</sup> Of particular interest in CR will be to understand whether imaging after cardiac events (e.g. echocardiography) contains information of value for prediction of outcome, risk of HF and likelihood of response to exercise interventions.

Another approach of unsupervised machine learning is to find clusters of similar data items: subjects in the same cluster are similar to each other, and dissimilar to subjects in other clusters. This can aid in discovering subtypes of patients with a certain disease. For example, machine learning has been able to identify clusters of patients with HF based on their baseline characteristics and test results (including cardiopulmonary exercise tests).<sup>147-150</sup> Phenotyping through machine learning predicted the prognosis of HF patients, and performed better compared to traditional predictors such as ejection fraction.<sup>149</sup>

A major concern of artificial intelligence is the 'black box' phenomenon. More complex machine learning processes, such as neural networks, build layer upon layer of automated decisions up to a

point where it is impossible to retrace the individual steps.<sup>151</sup> Thus, while some neural networks have been proven to outperform humans (for example in image recognition<sup>152</sup>), it is often hard to assess *how* the computer reached its decision or classification. One technique to overcome the ‘black box’ is to ask the computer to simultaneously create a simpler ‘surrogate’ model to gain insight in the reasoning process.<sup>153</sup>

Also, while the decision process can be fully automated and intelligent, large datasets still need to be imputed to train machine learning models. Availability of enough training data is currently still an issue, but the increased promotion of open science and data sharing will hopefully provide an answer to this problem soon.

Finally, a major challenge will be to convert artificial intelligence-derived predictions and recommendations into effective action. Better phenotyping and improved risk stratification do not automatically lead to improve health. To truly achieve a health care transformation, behavioural changes are needed at both patient and physician level.<sup>154</sup> For example, artificial intelligence may improve exercise prescription, but a patient’s health will only improve if his or her physician implements this improved prescription in practice, and he or she adheres to the prescribed training.

- *To summarize, early applications in CR research and advanced examples from imaging and phenotyping studies show that the advent of ‘big data’ and machine learning will likely change current practice. Major challenges include picking up useful signals between increased noise in big datasets, the ‘black box’ phenomenon, and implementing behavioural changes based on computerized recommendations. We suggest some future research areas in **Table 2**.*

*Table 2: Suggested research areas for application of data mining and machine learning in exercise-based CR*

<b>Data Source</b>	<b>Suggested Application</b>	<b>Examples</b>
Cardiopulmonary exercise test raw data	Improve risk stratification	Discover novel prognostic variables
	Detection of subliminal patterns	Exercise oscillatory ventilation Autonomic dysfunction
Baseline data (including imaging) of large exercise studies	Discover novel subtypes / phenogroups	Different phenotypes of heart failure <sup>147–150</sup>
	Improve diagnostic process	AI-driven diagnosis of left ventricular dysfunction
Outcome data of large exercise studies	Improve prescription of CR	AI-driven exercise prescription, similar to human-driven Expert tool <sup>141,142</sup>
Omics (genomics, epigenomics, proteomics, metabolomics)	Prediction of low or high response to CR	Presence of certain SNP indicates better response <sup>33,34</sup>
	Improve prescription of CR	Presence of certain SNP indicates better response to certain training modality

AI = artificial intelligence, CR = cardiac rehabilitation, SNP = single nucleotide polymorphism

### **3.2 Sense and nonsense of animal models**

Appropriate animal models are important to unravel the molecular mechanisms for how exercise-based CR mediates its beneficial effects. Small rodents in particular are attractive models for cardiovascular research, possessing unique properties such as easy handling, short gestation time and low costs. Perhaps most important is the availability of transgenic mice and rats, which allow the possibility to study the involvement of specific molecules in transmitting the positive effect of exercise training, which otherwise would not be possible in humans. Nevertheless, a certain scepticism is warranted based on whether animal models appropriately translate to humans, which has resulted (and rightly so) in the value of such research being questioned.<sup>155–157</sup>

An ideal disease model should mimic the human condition genetically, experimentally and physiologically. Therefore, using inbred mouse strains may not reflect the response generated in a genetically polymorphic human population, which may be one reason for the failure of many promising preclinical drugs when translated into human clinical trials. In support, a recently published comment stated that >80% of potential therapeutics fail when tested in humans, even after animal studies have provided evidence that the treatment is safe and effective.<sup>158</sup> One future avenue to circumvent such translational problems may reside in the use of humanized models, whereby mice expressing human transgenes or engrafted human cells/tissue are used in preclinical research.<sup>159</sup> Obviously, generating diseased animal models due to genetic defects is much easier than trying to mimic a more complex disease pattern, where several comorbidities contribute to the final clinical phenotype. One contemporary example of such a complex disease is heart failure with preserved ejection fraction (HFpEF). Since the development of HFpEF is driven by several comorbidities, which include hypertension, diabetes, obesity and ageing,<sup>160–162</sup> it remains difficult to define an animal model that appropriately mimics the HFpEF phenotype. As of yet, the animal models used to probe molecular changes occurring in HFpEF and in response to exercise training have been predominantly based on a single risk factor such as aging or hypertension.<sup>83,163,164</sup> More recently this line of research included a more clinically relevant animal model, in a way that HFpEF develops due to the onset of multiple comorbidities that mirror a metabolic syndrome.<sup>84,165–167</sup> Another problem with appropriate animal models may be that most models develop over a short time period, whereas in humans sometimes several years or decades pass before a clear phenotype is established.

Animals used for cardiovascular exercise studies most commonly range from small rodents (e.g. mice, rats) to large animals (e.g. rabbits, canine, goats, sheep, pigs, horses).<sup>168–173</sup> In these animal models exercise can either be voluntary (e.g., animal cage is equipped with a running wheel) or forced (e.g., animal is placed onto a treadmill for a specific period). Many exercise training studies have been employed using a variety of animal models of diseases that include HF,<sup>165,174,175</sup> diabetes,<sup>176,177</sup> and neurodegenerative diseases.<sup>178</sup> Beside the classical animal models (mouse and rat) used to analyse the effect of exercise training on molecular and physiological parameters, more recently other species have been used such as drosophila and zebrafish.<sup>179–182</sup> Exercise training in drosophila results in improvements of physiological and molecular measures, which include enhanced climbing speed, flight performance, aconitase levels, and cardiac contractility. Clearly, while the main advantage of using flies as an animal model is that you can train several thousand flies simultaneously, the question of whether and to what extent these findings translate to humans looms large. We also have to keep in mind that it is even more difficult in animal models to control for activity levels. In human studies

most of the patients recruited into an exercise study exhibit a very low exercise level, which is difficult to control for in animals.

- *To summarize, the 'sense' to use animal models to investigate the benefits associated with exercise in disease is difficult to refute: animal studies have often provided the initial clues to help elucidate how exercise exerts its benefits for treating disease. However, animal research can also provide much 'nonsense' when translated to humans. Future studies should therefore continue focusing on developing more complex and robust animal models of disease that closely reflect the human condition.*

#### **4. Conclusion and Outlook**

Exercise-based CR has consistently shown positive effects on the course of cardiovascular disease. However, recent studies showed that there is a large variation in training effects at the individual level, with up to one third of patients failing to demonstrate a significant increase in exercise capacity despite adequate compliance. Therefore, in order to improve the effects of exercise-based CR it is crucial to (1) gain more in-depth knowledge on the determinants and mechanisms governing the response to exercise in the organs - beyond the skeletal muscle, heart and vascular system - and (2) to acknowledge their interaction at a systemic level.

Heritable and non-heritable factors each determine approximately 50% of inter-individual heterogeneity in  $\Delta\text{VO}_2\text{peak}$ . High-throughput technologies in combination with improved bio-informatics and bio-statistical approaches can help identify major regulatory nodes among large datasets that cannot be readily interpreted otherwise.

Sex-specific differences in the response to exercise in cardiovascular therapy are severely understudied. Although endocrine, anatomical and molecular differences between men and women are assumed to play a role, the exact mechanisms remain largely unknown. Future research therefore needs to include sufficient numbers of female patients to address these issues.

Based on these studies, a concise, easy-to-use panel of markers that could help personalize exercise parameters could be developed. This panel could include regulatory nodes identified in clusters of patients through their classical risk profile, but also inflammatory and metabolic status, and genetic traits identified through advanced bio-statistics. Finally, while animal models have inherent limitations complicating translation to humans, complex and robust animal models closely reflecting human cardiovascular diseases will be needed to test the hypotheses mentioned and to gain further insight in the complex physiology of exercise-based CR.

## References

1. Anderson L, Oldridge N, Thompson DR, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease. *J Am Coll Cardiol* 2016; 67: 1–12.
2. Rauch B, Davos CH, Doherty P, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS). *Eur J Prev Cardiol* 2016; 23: 1914–1939.
3. Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *JAMA* 2009; 301: 2024–35.
4. Harber MP, Kaminsky LA, Arena R, et al. Impact of Cardiorespiratory Fitness on All-Cause and Disease-Specific Mortality: Advances Since 2009. *Prog Cardiovasc Dis* 2017; 60: 11–20.
5. Schuler G, Adams V, Goto Y. Role of exercise in the prevention of cardiovascular disease: results, mechanisms, and new perspectives. *Eur Heart J* 2013; 34: 1790–1799.
6. Lavie CJ, Arena R, Swift DL, et al. Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. *Circ Res* 2015; 117: 207–19.
7. Abreu A, Pesah E, Supervia M, et al. Cardiac rehabilitation availability and delivery in Europe: How does it differ by region and compare with other high-income countries? *Eur J Prev Cardiol* 2019; 204748731982745.
8. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2016; 37: 2315–2381.
9. Piepoli MF, Corrà U, Dendale P, et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. *Eur J Prev Cardiol* 2016; 23: 1994–2006.
10. Coeckelberghs E, Buys R, Goetschalckx K, et al. Prognostic value of the oxygen uptake efficiency slope and other exercise variables in patients with coronary artery disease. *Eur J Prev Cardiol* 2016; 23: 237–244.
11. Tabet J-Y, Meurin P, Beauvais F, et al. Absence of Exercise Capacity Improvement After Exercise Training Program. *Circ Heart Fail* 2008; 1: 220–226.
12. De Schutter A, Kachur S, Lavie CJ, et al. Cardiac rehabilitation fitness changes and subsequent survival. *Eur Heart J - Qual Care Clin Outcomes* 2018; 4: 173–179.
13. Vanhees L, Stevens A, Schepers D, et al. Determinants of the effects of physical training and of the complications requiring resuscitation during exercise in patients with cardiovascular disease. *Eur J Cardiovasc Prev Rehabil* 2004; 11: 304–312.
14. Ciani O, Piepoli M, Smart N, et al. Validation of Exercise Capacity as a Surrogate Endpoint in Exercise-Based Rehabilitation for Heart Failure. *JACC Heart Fail* 2018; 6: 596–604.
15. Bouchard C, Rankinen T. Individual differences in response to regular physical activity. *Med Sci Sports Exerc* 2001; 33: S446–S451.
16. Schmid J-P, Zurek M, Saner H. Chronotropic incompetence predicts impaired response to exercise training in heart failure patients with sinus rhythm. *Eur J Prev Cardiol* 2013; 20: 585–592.
17. Witvrouwen I, Pattyn N, Gevaert AB, et al. Predictors of response to exercise training in patients with coronary artery disease – a subanalysis of the SAINTEX-CAD study. *Eur J Prev Cardiol*. Epub ahead of print 12 February 2019. DOI: 10.1177/2047487319828478.
18. Corrà U, Agostoni PG, Anker SD, et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2018; 20: 3–15.
19. Williams CJ, Gurd BJ, Bonafiglia JT, et al. A Multi-Center Comparison of O2peak Trainability Between Interval Training and Moderate Intensity Continuous Training. *Front Physiol* 2019; 10: 1–13.
20. Montero D, Lundby C. Refuting the myth of non-response to exercise training: ‘non-responders’ do respond to higher dose of training. *J Physiol* 2017; 595: 3377–3387.
21. Kraal JJ, Vromen T, Spee R, et al. The influence of training characteristics on the effect of exercise training in patients with coronary artery disease: Systematic review and meta-regression analysis. *Int J Cardiol* 2017; 245: 52–58.
22. Wilson JR, Groves J, Rayos G. Circulatory Status and Response to Cardiac Rehabilitation in Patients With Heart Failure. *Circulation* 1996; 94: 1567–1572.
23. Gordon A, Tyni-Lenné R, Jansson E, et al. Beneficial effects of exercise training in heart failure patients with low cardiac output response to exercise - a comparison of two training models. *J Intern Med* 1999; 246: 175–82.
24. Schutte NM, Nederend I, Hudziak JJ, et al. Twin-sibling study and meta-analysis on the heritability of maximal oxygen consumption. *Physiol Genomics* 2016; 48: 210–219.
25. Bouchard C, Daw EW, Rice T, et al. Familial resemblance for VO2max in the sedentary state: the HERITAGE family study. *Med Sci Sports Exerc* 1998; 30: 252–8.
26. Bouchard C, An P, Rice T, et al. Familial aggregation of VO2max response to exercise training: results from the HERITAGE Family Study. *J Appl Physiol* 1999; 87: 1003–1008.
27. Bouchard C, Rankinen T, Timmons JA. Genomics and Genetics in the Biology of Adaptation to Exercise. *Compr Physiol* 2011; 1: 1603–48.
28. An P, Rice T, Gagnon J, et al. Familial Aggregation of Stroke Volume and Cardiac Output During Submaximal Exercise: The HERITAGE Family Study. *Int J Sports Med* 2000; 21: 566–572.
29. Skinner JS, Jaskólski A, Jaskólska A, et al. Age, sex, race, initial fitness, and response to training: the HERITAGE Family Study. *J Appl Physiol* 2001; 90: 1770–1776.
30. Montgomery HE, Clarkson P, Dollery CM, et al. Association of Angiotensin-Converting Enzyme Gene

- I/D Polymorphism With Change in Left Ventricular Mass in Response to Physical Training. *Circulation* 1997; 96: 741–747.
31. Bray MS, Hagberg JM, Pérusse L, et al. The human gene map for performance and health-related fitness phenotypes: the 2006-2007 update. *Med Sci Sports Exerc* 2009; 41: 35–73.
  32. Kilpeläinen TO, Qi L, Brage S, et al. Physical Activity Attenuates the Influence of FTO Variants on Obesity Risk: A Meta-Analysis of 218,166 Adults and 19,268 Children. *PLoS Med* 2011; 8: e1001116, 1–14.
  33. Timmons JA, Knudsen S, Rankinen T, et al. Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans. *J Appl Physiol* 2010; 108: 1487–1496.
  34. Bouchard C, Sarzynski MA, Rice TK, et al. Genomic predictors of the maximal O<sub>2</sub> uptake response to standardized exercise training programs. *J Appl Physiol* 2011; 110: 1160–1170.
  35. Hoppeler H. Deciphering VO<sub>2</sub>max: limits of the genetic approach. *J Exp Biol* 2018; 221: jeb164327.
  36. Rankinen T, Fuku N, Wolfarth B, et al. No Evidence of a Common DNA Variant Profile Specific to World Class Endurance Athletes. *PLoS One* 2016; 11: e0147330.
  37. Sapp RM, Shill DD, Roth SM, et al. Circulating microRNAs in acute and chronic exercise: more than mere biomarkers. *J Appl Physiol* 2017; 122: 702–717.
  38. Silva GJJ, Bye A, el Azzouzi H, et al. MicroRNAs as Important Regulators of Exercise Adaptation. *Prog Cardiovasc Dis* 2017; 60: 130–151.
  39. Souza RWA, Fernandez GJ, Cunha JPQ, et al. Regulation of cardiac microRNAs induced by aerobic exercise training during heart failure. *Am J Physiol Circ Physiol* 2015; 309: H1629–H1641.
  40. Taurino C, Miller WH, McBride MW, et al. Gene expression profiling in whole blood of patients with coronary artery disease. *Clin Sci* 2010; 119: 335–343.
  41. Xu T, Zhou Q, Che L, et al. Circulating miR-21, miR-378, and miR-940 increase in response to an acute exhaustive exercise in chronic heart failure patients. *Oncotarget* 2016; 7: 12414–12425.
  42. Van Laethem C, Van De Veire N, De Backer G, et al. Response of the oxygen uptake efficiency slope to exercise training in patients with chronic heart failure. *Eur J Heart Fail* 2007; 9: 625–629.
  43. Rakobowchuk M, Harris E, Taylor A, et al. Moderate and heavy metabolic stress interval training improve arterial stiffness and heart rate dynamics in humans. *Eur J Appl Physiol* 2013; 113: 839–849.
  44. Alves AJ, Ribeiro F, Goldhammer E, et al. Exercise Training Improves Diastolic Function in Heart Failure Patients. *Med Sci Sports Exerc* 2012; 44: 776–785.
  45. Kränkel N, Bahls M, Van Craenenbroeck EM, et al. Exercise training to reduce cardiovascular risk in patients with metabolic syndrome and type 2 diabetes mellitus: How does it work? *Eur J Prev Cardiol* 2019; 26: 701–708.
  46. Conraads VM, Beckers P, Bosmans J, et al. Combined endurance/resistance training reduces plasma TNF- $\alpha$  receptor levels in patients with chronic heart failure and coronary artery disease. *Eur Heart J* 2002; 23: 1854–1860.
  47. Sparling PB. A Meta-Analysis of Studies Comparing Maximal Oxygen Uptake in Men and Women. *Res Q Exerc Sport* 1980; 51: 542–552.
  48. Piña IL, Bittner V, Clare RM, et al. Effects of Exercise Training on Outcomes in Women With Heart Failure. *JACC Heart Fail* 2014; 2: 180–186.
  49. Colbert JD, Martin B-J, Haykowsky MJ, et al. Cardiac rehabilitation referral, attendance and mortality in women. *Eur J Prev Cardiol* 2015; 22: 979–986.
  50. Witvrouwen I, Van Craenenbroeck EM, Abreu A, et al. Exercise training in women with cardiovascular disease: Differential response and barriers – review and perspective. *Eur J Prev Cardiol*. Epub ahead of print 19 March 2019. DOI: 10.1177/2047487319838221.

51. Beale AL, Meyer P, Marwick TH, et al. Sex Differences in Cardiovascular Pathophysiology. *Circulation* 2018; 138: 198–205.
52. Regitz-Zagrosek V, Kararigas G. Mechanistic Pathways of Sex Differences in Cardiovascular Disease. *Physiol Rev* 2017; 97: 1–37.
53. Wiinberg N, Høegholm A, Christensen HR, et al. 24-h ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. *Am J Hypertens* 1995; 8: 978–986.
54. Lavie CJ, Milani R. Secondary Coronary Prevention in Women: It Starts with Cardiac Rehabilitation, Exercise, and Fitness. *J Womens Health* 2009; 18: 1115–1117.
55. Lavie CJ, Milani R V. Benefits of Cardiac Rehabilitation and Exercise Training in Elderly Women. *Am J Cardiol* 1997; 79: 664–666.
56. Gregg EW, Gu Q, Cheng YJ, et al. Mortality Trends in Men and Women with Diabetes, 1971 to 2000. *Ann Intern Med* 2007; 147: 149.
57. Ll Lloyd GW. Preventive cardiology and cardiac rehabilitation programmes in women. *Maturitas* 2009; 63: 28–33.
58. Bots SH, Peters SAE, Woodward M. Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. *BMJ Glob Heal* 2017; 2: e000298, 1–8.
59. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol* 2017; 14: 591–602.
60. Johnston N, Jónelid B, Christersson C, et al. Effect of Gender on Patients With ST-Elevation and Non-ST-Elevation Myocardial Infarction Without Obstructive Coronary Artery Disease. *Am J Cardiol* 2015; 115: 1661–1666.
61. Pernicova I, Garg S, Bourantas C V., et al. Takotsubo Cardiomyopathy: A Review of the Literature. *Angiology* 2010; 61: 166–173.
62. Redfield MM, Jacobsen SJ, Borlaug BA, et al. Age- and Gender-Related Ventricular-Vascular Stiffening. *Circulation* 2005; 112: 2254–2262.
63. Chung AK, Das SR, Leonard D, et al. Women Have Higher Left Ventricular Ejection Fractions Than Men Independent of Differences in Left Ventricular Volume. *Circulation* 2006; 113: 1597–1604.
64. Föll D, Jung B, Schilli E, et al. Magnetic Resonance Tissue Phase Mapping of Myocardial Motion. *Circ Cardiovasc Imaging* 2010; 3: 54–64.
65. James AF, Choisy SCM, Hancox JC. Recent advances in understanding sex differences in cardiac repolarization. *Prog Biophys Mol Biol* 2007; 94: 265–319.
66. Stramba-Badiale M, Locati EH, Martinelli A, et al. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. *Eur Heart J* 1997; 18: 1000–1006.
67. Ayaz O, Howlett SE. Testosterone modulates cardiac contraction and calcium homeostasis: cellular and molecular mechanisms. *Biol Sex Differ* 2015; 6: 9.
68. Borrás C, Sastre J, García-Sala D, et al. Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. *Free Radic Biol Med* 2003; 34: 546–52.
69. Trexler CL, Odell AT, Jeong MY, et al. Transcriptome and Functional Profile of Cardiac Myocytes Is Influenced by Biological Sex. *Circ Cardiovasc Genet* 2017; 10: 001770.
70. Olivetti G, Giordano G, Corradi D, et al. Gender differences and aging: Effects on the human heart. *J Am Coll Cardiol* 1995; 26: 1068–1079.
71. Lempereur M, Magne J, Cornelis K, et al. Impact of gender difference in hospital outcomes following percutaneous coronary intervention. Results of the Belgian Working Group on Interventional Cardiology (BWGIC) registry. *EuroIntervention* 2016; 12: e216–e223.
72. Regitz-Zagrosek V, Lehmkuhl E, Hocher B, et al. Gender as a risk factor in young, not in old, women undergoing coronary artery bypass grafting. *J Am Coll Cardiol* 2004; 44: 2413–2414.
73. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. *N Engl J Med* 2009; 361: 1329–1338.
74. Pines A. Hormone therapy and the cardiovascular system. *Maturitas* 2002; 43 Suppl 1: S3-10.
75. Manhem K, Brandin L, Ghanoum B, et al. Acute effects of transdermal estrogen on hemodynamic and vascular reactivity in elderly postmenopausal healthy women. *J Hypertens* 2003; 21: 387–394.
76. Adams V, Reich B, Uhlemann M, et al. Molecular effects of exercise training in patients with cardiovascular disease: focus on skeletal muscle, endothelium, and myocardium. *Am J Physiol Circ Physiol* 2017; 313: H72–H88.
77. Duscha BD, Annex BH, Green HJ, et al. Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. *J Am Coll Cardiol* 2002; 39: 1170–1174.
78. Duscha BD, Annex BH, Keteyian SJ, et al. Differences in skeletal muscle between men and women with chronic heart failure. *J Appl Physiol* 2001; 90: 280–286.
79. Keteyian SJ, Duscha BD, Brawner CA, et al. Differential effects of exercise training in men and women with chronic heart failure. *Am Heart J* 2003; 145: 912–918.
80. Nagai S, Ikeda K, Horie-Inoue K, et al. Estrogen modulates exercise endurance along with mitochondrial uncoupling protein 3 downregulation in skeletal muscle of female mice. *Biochem Biophys Res Commun* 2016; 480: 758–764.
81. Cardinale DA, Larsen FJ, Schiffer TA, et al. Superior Intrinsic Mitochondrial Respiration in Women Than in Men. *Front Physiol* 2018; 9: 1133, 1–12.
82. Kishimoto S, Kajikawa M, Maruhashi T, et al. Endothelial dysfunction and abnormal vascular structure are simultaneously present in patients with heart failure with preserved ejection fraction. *Int J Cardiol* 2017; 231: 181–187.
83. Adams V, Alves M, Fischer T, et al. High-intensity interval training attenuates endothelial dysfunction in a Dahl salt-sensitive rat model of heart failure with preserved ejection fraction. *J Appl Physiol* 2015; 119: 745–752.
84. Schmederer Z, Rolim N, Bowen TS, et al. Endothelial function is disturbed in a hypertensive diabetic animal model of HFpEF: Moderate continuous vs. high intensity interval training. *Int J Cardiol* 2018; 273: 147–

- 154.
85. Tarnopolsky MA. Sex Differences in Exercise Metabolism and the Role of 17-Beta Estradiol. *Med Sci Sport Exerc* 2008; 40: 648–654.
  86. Sumner J, Harrison A, Doherty P. The effectiveness of modern cardiac rehabilitation: A systematic review of recent observational studies in non-attenders versus attenders. *PLoS One* 2017; 12: e0177658, 1–14.
  87. Minges KE, Strait KM, Owen N, et al. Gender differences in physical activity following acute myocardial infarction in adults: A prospective, observational study. *Eur J Prev Cardiol* 2017; 24: 192–203.
  88. Oosenbrug E, Marinho RP, Zhang J, et al. Sex Differences in Cardiac Rehabilitation Adherence: A Meta-analysis. *Can J Cardiol* 2016; 32: 1316–1324.
  89. Feola M, Garnero S, Daniele B, et al. Gender differences in the efficacy of cardiovascular rehabilitation in patients after cardiac surgery procedures. *J Geriatr Cardiol* 2015; 12: 575–9.
  90. Anjo D, Santos M, Rodrigues P, et al. The benefits of cardiac rehabilitation in coronary heart disease: A gender issue? *Rev Port Cardiol (English Ed)* 2014; 33: 79–87.
  91. Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. *Cochrane Database Syst Rev* 2019; 2019: CD003331.
  92. Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database Syst Rev* 2016; 2016: CD001800.
  93. Ross R. Atherosclerosis — An Inflammatory Disease. *N Engl J Med* 1999; 340: 115–126.
  94. Leal LG, Lopes MA, Batista ML. Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases. *Front Physiol* 2018; 9: 1307, 1–17.
  95. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med* 2017; 377: 1119–1131.
  96. Ridker PM. Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials. *J Intern Med* 2019; 285: 503–509.
  97. Fredman G, Tabas I. Boosting Inflammation Resolution in Atherosclerosis. *Am J Pathol* 2017; 187: 1211–1221.
  98. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. *Nature* 2014; 510: 92–101.
  99. Durrer C, Francois M, Neudorf H, et al. Acute high-intensity interval exercise reduces human monocyte Toll-like receptor 2 expression in type 2 diabetes. *Am J Physiol Integr Comp Physiol* 2017; 312: R529–R538.
  100. McKenzie Al, Briggs RA, Barrows KM, et al. A pilot study examining the impact of exercise training on skeletal muscle genes related to the TLR signaling pathway in older adults following hip fracture recovery. *J Appl Physiol* 2017; 122: 68–75.
  101. Rada I, Deldicque L, Francaux M, et al. Toll like receptor expression induced by exercise in obesity and metabolic syndrome: A systematic review. *Exerc Immunol Rev* 2018; 24: 60–71.
  102. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N Engl J Med* 2019; 380: 11–22.
  103. Berrueta L, Muskaj I, Olenich S, et al. Stretching Impacts Inflammation Resolution in Connective Tissue. *J Cell Physiol* 2016; 231: 1621–1627.
  104. Gangemi S, Lucioti G, D’Urbano E, et al. Physical exercise increases urinary excretion of lipoxin A 4 and related compounds. *J Appl Physiol* 2003; 94: 2237–2240.
  105. Markworth JF, Vella L, Lingard BS, et al. Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment. *Am J Physiol Integr Comp Physiol* 2013; 305: R1281–R1296.
  106. Ruffino JS, Davies NA, Morris K, et al. Moderate-intensity exercise alters markers of alternative activation in circulating monocytes in females: a putative role for PPAR $\gamma$ . *Eur J Appl Physiol* 2016; 116: 1671–1682.
  107. Dalli J, Serhan C. Macrophage Proresolving Mediators—the When and Where. *Microbiol Spectr* 2016; 4: MCHD-0001-2014, 1-17.
  108. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. *Science* 2009; 324: 1029–1033.
  109. Akins NS, Nielson TC, Le H V. Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer. *Curr Top Med Chem* 2018; 18: 494–504.
  110. Board M, Humm S, Newsholme EA. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. *Biochem J* 1990; 265: 503–9.
  111. Allison KE, Coomber BL, Bridle BW. Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes. *Immunology* 2017; 152: 175–184.
  112. Bustos R, Sobrino F. Stimulation of glycolysis as an activation signal in rat peritoneal macrophages. Effect of glucocorticoids on this process. *Biochem J* 1992; 282 ( Pt 1): 299–303.
  113. Mills EL, O’Neill LA. Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal. *Eur J Immunol* 2016; 46: 13–21.
  114. Jha AK, Huang SC-C, Sergushichev A, et al. Network Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules that Regulate Macrophage Polarization. *Immunity* 2015; 42: 419–430.
  115. EL Kasmi KC, Stenmark KR. Contribution of metabolic reprogramming to macrophage plasticity and function. *Semin Immunol* 2015; 27: 267–275.
  116. Rodriguez-Prados J-C, Traves PG, Cuenca J, et al. Substrate Fate in Activated Macrophages: A Comparison between Innate, Classic, and Alternative Activation. *J Immunol* 2010; 185: 605–614.
  117. Vats D, Mukundan L, Odegaard JI, et al. Oxidative metabolism and PGC-1 $\beta$  attenuate macrophage-mediated inflammation. *Cell Metab* 2006; 4: 13–24.
  118. Antoniadou C, Kotanidis CP, Berman DS. State-of-the-art review article. Atherosclerosis affecting fat: What

- can we learn by imaging perivascular adipose tissue? *J Cardiovasc Comput Tomogr*. Epub ahead of print March 2019. DOI: 10.1016/j.jcct.2019.03.006.
119. Kawanishi N, Yano H, Yokogawa Y, et al. Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice. *Exerc Immunol Rev* 2010; 16: 105–18.
  120. Oliveira AG, Araujo TG, Carvalho BM, et al. Acute exercise induces a phenotypic switch in adipose tissue macrophage polarization in diet-induced obese rats. *Obesity* 2013; 21: 2545–2556.
  121. Walton RG, Kosmac K, Mula J, et al. Human skeletal muscle macrophages increase following cycle training and are associated with adaptations that may facilitate growth. *Sci Rep* 2019; 9: 969, 1–14.
  122. Gao D, Bailey CJ, Griffiths HR. Metabolic memory effect of the saturated fatty acid, palmitate, in monocytes. *Biochem Biophys Res Commun* 2009; 388: 278–282.
  123. Jing Y, Wu F, Li D, et al. Metformin improves obesity-associated inflammation by altering macrophages polarization. *Mol Cell Endocrinol* 2018; 461: 256–264.
  124. Wang J, Ma A, Zhao M, et al. AMPK activation reduces the number of atheromata macrophages in ApoE deficient mice. *Atherosclerosis* 2017; 258: 97–107.
  125. Börgeson E, Wallenius V, Syed GH, et al. AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin. *Diabetologia* 2017; 60: 729–739.
  126. Jose C, Hébert-Chatelain E, Bellance N, et al. AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation. *Biochim Biophys Acta - Bioenerg* 2011; 1807: 707–718.
  127. Eleftheriadis T, Pissas G, Liakopoulos V, et al. IDO decreases glycolysis and glutaminolysis by activating GCN2K, while it increases fatty acid oxidation by activating AhR, thus preserving CD4+ T- cell survival and proliferation. *Int J Mol Med* 2018; 42: 557–568.
  128. Bae S, Lee MJ, Mun SH, et al. MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor  $ERR\alpha$ . *J Clin Invest* 2017; 127: 2555–2568.
  129. Matlib MA. Action of bepridil, a new calcium channel blocker on oxidative phosphorylation, oligomycin-sensitive adenosine triphosphatase activity, swelling,  $Ca^{++}$  uptake and  $Na^{+}$ -induced  $Ca^{++}$  release processes of rabbit heart mitochondria in vitro. *J Pharmacol Exp Ther* 1985; 233: 376–81.
  130. Han F, Li G, Dai S, et al. Genome-wide metabolic model to improve understanding of CD4 + T cell metabolism, immunometabolism and application in drug design. *Mol Biosyst* 2016; 12: 431–443.
  131. Mei HE, Leipold MD, Schulz AR, et al. Barcoding of Live Human Peripheral Blood Mononuclear Cells for Multiplexed Mass Cytometry. *J Immunol* 2015; 194: 2022–2031.
  132. Van den Bossche J, Baardman J, de Winther MPJ. Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis. *J Vis Exp* 2015; 2015: e53424, 1–7.
  133. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med* 2019; 25: 44–56.
  134. Johnson KW, Torres Soto J, Glicksberg BS, et al. Artificial Intelligence in Cardiology. *J Am Coll Cardiol* 2018; 71: 2668–2679.
  135. Dey D, Slomka PJ, Leeson P, et al. Artificial Intelligence in Cardiovascular Imaging. *J Am Coll Cardiol* 2019; 73: 1317–1335.
  136. Krittanawong C, Zhang H, Wang Z, et al. Artificial Intelligence in Precision Cardiovascular Medicine. *J Am Coll Cardiol* 2017; 69: 2657–2664.
  137. Goud R, de Keizer NF, ter Riet G, et al. Effect of guideline based computerised decision support on decision making of multidisciplinary teams: cluster randomised trial in cardiac rehabilitation. *BMJ* 2009; 338: b1440–b1440.
  138. Kostopoulos K, Chouvarda I, Koutkias V, et al. An ontology-based framework aiming to support personalized exercise prescription: Application in cardiac rehabilitation. In: *2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society*. 30 Aug-3 Sep 2011, Boston, MA, USA: IEEE, pp. 1567–1570.
  139. Lofaro D, Groccia MC, Guido R, et al. Machine learning approaches for supporting patient-specific cardiac rehabilitation programs. In: *2016 Computing in Cardiology Conference*. 11-14 Sep 2016, Vancouver, BC, Canada: IEEE, p. 7868701.
  140. Lo C-L, Tseng H-T. Predicting rehabilitation treatment helpfulness to stroke patients: A supervised learning approach. *Artif Intell Res* 2017; 6: 1–9.
  141. Hansen D, Dendale P, Coninx K, et al. The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. *Eur J Prev Cardiol* 2017; 24: 1017–1031.
  142. Hansen D, Coninx K, Dendale P. The EAPC EXPERT tool. *Eur Heart J* 2017; 38: 2318–2320.
  143. Bonomi AG, Goldenberg S, Papini G, et al. Predicting energy expenditure from photo-plethysmographic measurements of heart rate under beta blocker therapy: Data driven personalization strategies based on mixed models. In: *2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)*. 25-29 Aug 2015, Milan, Italy: IEEE, pp. 7642–7646.
  144. Lewandowski AJ, Augustine D, Lamata P, et al. Preterm Heart in Adult Life. *Circulation* 2013; 127: 197–206.
  145. Coffey S, Lewandowski AJ, Garratt S, et al. Protocol and quality assurance for carotid imaging in 100,000 participants of UK Biobank: development and assessment. *Eur J Prev Cardiol* 2017; 24: 1799–1806.
  146. Alsharqi M, Woodward WJ, Mumith JA, et al. Artificial intelligence and echocardiography. *Echo Res Pract* 2018; R115–R125.
  147. Tromp J, Tay WT, Ouwerkerk W, et al. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. *PLoS Med* 2018; 15: e1002541, 1–22.

148. Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction. *Circulation* 2015; 131: 269–279.
149. Ahmad T, Lund LH, Rao P, et al. Machine learning methods improve prognostication, identify clinically distinct phenotypes, and detect heterogeneity in response to therapy in a large cohort of heart failure patients. *J Am Heart Assoc* 2018; 7: 1–15.
150. Kao DP, Lewsey JD, Anand IS, et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. *Eur J Heart Fail* 2015; 17: 925–935.
151. Castelveccchi D. Can we open the black box of AI? *Nature* 2016; 538: 20–23.
152. He K, Zhang X, Ren S, et al. Delving Deep into Rectifiers: Surpassing Human-Level Performance on ImageNet Classification. In: *2015 IEEE International Conference on Computer Vision (ICCV)*. 7–13 Dec 2015, Santiago, Chile: IEEE, pp. 1026–1034.
153. Haro Alonso D, Wernick MN, Yang Y, et al. Prediction of cardiac death after adenosine myocardial perfusion SPECT based on machine learning. *J Nucl Cardiol*. Epub ahead of print 14 March 2018. DOI: 10.1007/s12350-018-1250-7.
154. Emanuel EJ, Wachter RM. Artificial Intelligence in Health Care. *JAMA*. Epub ahead of print 20 May 2019. DOI: 10.1001/jama.2019.4914.
155. Buffenstein R, Nelson OL, Corbit KC. Questioning the preclinical paradigm: natural, extreme biology as an alternative discovery platform. *Aging* 2014; 6: 913–920.
156. Pound P, Bracken MB. Is animal research sufficiently evidence based to be a cornerstone of biomedical research? *BMJ* 2014; 348: g3387–g3387.
157. Young NS. Mouse Medicine and Human Biology. *Semin Hematol* 2013; 50: 88–91.
158. Perrin S. Preclinical research: Make mouse studies work. *Nature* 2014; 507: 423–425.
159. Walsh NC, Kenney LL, Jangalwe S, et al. Humanized Mouse Models of Clinical Disease. *Annu Rev Pathol Mech Dis* 2017; 12: 187–215.
160. Juillière Y, Venner C, Filippetti L, et al. Heart failure with preserved ejection fraction: A systemic disease linked to multiple comorbidities, targeting new therapeutic options. *Arch Cardiovasc Dis* 2018; 111: 766–781.
161. Gevaert AB, Lemmens K, Vrints CJ, et al. Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training. *Oxid Med Cell Longev* 2017; 4865756, 1–17.
162. Gevaert AB, Boen JRA, Segers VF, et al. Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology. *Front Physiol* 2019; 10: 638, 1–14.
163. Gevaert AB, Shakeri H, Leloup AJ, et al. Endothelial Senescence Contributes to Heart Failure With Preserved Ejection Fraction in an Aging Mouse Model. *Circ Heart Fail* 2017; 10: e003806, 1–10.
164. Bowen TS, Rolim NPL, Fischer T, et al. Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle. *Eur J Heart Fail* 2015; 17: 263–272.
165. Bowen TS, Herz C, Rolim NPL, et al. Effects of Endurance Training on Detrimental Structural, Cellular, and Functional Alterations in Skeletal Muscles of Heart Failure With Preserved Ejection Fraction. *J Card Fail* 2018; 24: 603–613.
166. Bowen TS, Brauer D, Rolim NPL, et al. Exercise Training Reveals Inflexibility of the Diaphragm in an Animal Model of Patients With Obesity-Driven Heart Failure With a Preserved Ejection Fraction. *J Am Heart Assoc* 2017; 6: e006416, 1–16.
167. Bode D, Guthof T, Pieske BM, et al. Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction. *J Vis Exp* 2018; 57953.
168. Billman GE. A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: Implications for future anti-arrhythmic drug development. *Pharmacol Ther* 2006; 111: 808–835.
169. Høydal MA, Wisløff U, Kemi OJ, et al. Running speed and maximal oxygen uptake in rats and mice: practical implications for exercise training. *Eur J Cardiovasc Prev Rehabil* 2007; 14: 753–760.
170. Delp MD, Armstrong RB, Godfrey DA, et al. Exercise increases blood flow to locomotor, vestibular, cardiorespiratory and visual regions of the brain in miniature swine. *J Physiol* 2001; 533: 849–859.
171. Janssen PM, Zeitz O, Keweloh B, et al. Influence of cyclosporine A on contractile function, calcium handling, and energetics in isolated human and rabbit myocardium. *Cardiovasc Res* 2000; 47: 99–107.
172. Barron BA, Laughlin MH, Gwartz PA. Exercise effect on canine and miniswine cardiac catecholamines and enkephalins. *Med Sci Sport Exerc* 1997; 29: 1338–1343.
173. Verboven M, Cuypers A, Deluyker D, et al. High intensity training improves cardiac function in healthy rats. *Sci Rep* 2019; 9: 5612, 1–8.
174. Seiler M, Bowen TS, Rolim N, et al. Skeletal Muscle Alterations Are Exacerbated in Heart Failure With Reduced Compared With Preserved Ejection Fraction. *Circ Heart Fail* 2016; 9: e003027, 1–10.
175. Vujic A, Lerchenmüller C, Wu T-D, et al. Exercise induces new cardiomyocyte generation in the adult mammalian heart. *Nat Commun* 2018; 9: 1659, 1–9.
176. Liu H-W, Chang S-J. Moderate Exercise Suppresses NF- $\kappa$ B Signaling and Activates the SIRT1-AMPK-PGC1 $\alpha$  Axis to Attenuate Muscle Loss in Diabetic db/db Mice. *Front Physiol* 2018; 9: 636, 1–9.
177. Chavanelle V, Boisseau N, Otero YF, et al. Effects of high-intensity interval training and moderate-intensity continuous training on glycaemic control and skeletal muscle mitochondrial function in db/db mice. *Sci Rep* 2017; 7: 204, 1–10.
178. Jahangiri Z, Gholamnezhad Z, Hosseini M. Neuroprotective effects of exercise in rodent models of memory deficit and Alzheimer's. *Metab Brain Dis* 2019; 34: 21–37.
179. Sujkowski A, Wessells R. Using Drosophila to Understand Biochemical and Behavioral Responses to Exercise. *Exerc Sport Sci Rev* 2018; 46: 1.
180. Gilbert MJH, Zerulla TC, Tierney KB. Zebrafish (Danio

- rerio) as a model for the study of aging and exercise: Physical ability and trainability decrease with age. *Exp Gerontol* 2014; 50: 106–113.
181. Boskovic S, Marín-Juez R, Jasnic J, et al. Characterization of zebrafish (*Danio rerio*) muscle ankyrin repeat proteins reveals their conserved response to endurance exercise. *PLoS One* 2018; 13: e0204312, 1–21.
182. van der Meulen T, Schipper H, van den Boogaart JGM, et al. Endurance exercise differentially stimulates heart and axial muscle development in zebrafish (*Danio rerio*). *Am J Physiol Integr Comp Physiol* 2006; 291: R1040–R1048.